Geron Corporation (NASDAQ: GERN) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
1.30
-0.02-1.52%
News
Down 1.5% — Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (globenewswire.com).
Medium confidence
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -0.10 | Insider Own | 5.39% | Shs Outstand | 641.52M | Perf Week | -3.70% |
| Market Cap | 833.98M | Forward P/E | 17.57 | EPS next Y | 0.07 | Insider Trans | 0.00% | Shs Float | 560.06M | Perf Month | -18.24% |
| Enterprise Value | 653.98M | PEG | - | EPS next Q | -0.01 | Inst Own | - | Short Float | 15.19% | Perf Quarter | 3.17% |
| Income | -70.00M | P/S | 4.09 | EPS this Y | 57.50% | Inst Trans | - | Short Ratio | 7.38 | Perf Half Y | -16.13% |
| Sales | 204.00M | P/B | 3.81 | EPS next Y | 274.12% | ROA | -13.47% | Short Interest | 85.09M | Perf YTD | -1.52% |
| Book/sh | 0.34 | P/C | 2.77 | EPS next 5Y | - | ROE | -30.31% | 52W High | 2.01 -35.32% | Perf Year | 2.36% |
| Cash/sh | 0.47 | P/FCF | - | EPS past 3/5Y | - | ROIC | -8.32% | 52W Low | 1.04 25.00% | Perf 3Y | -43.48% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 468.77% - | Gross Margin | 83.21% | Volatility | 4.05% 5.05% | Perf 5Y | -9.72% |
| Dividend TTM | - | EV/Sales | 3.21 | EPS Y/Y TTM | 62.96% | Oper. Margin | -18.29% | ATR (14) | 0.08 | Perf 10Y | -57.38% |
| Dividend Ex-Date | - | Quick Ratio | 5.16 | Sales Y/Y TTM | 164.94% | Profit Margin | -34.17% | RSI (14) | 38.26 | Recom | 2.32 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.92 | EPS Q/Q | - | SMA20 | -10.41% | Beta | 0.60 | Target Price | 5.89 |
| Payout | 0.00% | Debt/Eq | 1.11 | Sales Q/Q | 16.33% | SMA50 | -10.85% | Rel Volume | 1.53 | Prev Close | 1.32 |
| Employees | 258 | LT Debt/Eq | 1.03 | Earnings | Nov 04 | SMA200 | -10.19% | Avg Volume | 11.27M | Price | 1.30 |
| IPO Date | Jul 31, 1996 | Option/Short | No / Yes | EPS/Sales Surpr. | -125.23% 3.94% | Net Debt/EBITDA | -1.43 | Volume | 17,242,349 | Change | -1.52% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-08-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform | |
| Feb-27-25 | Reiterated | Barclays | Overweight | $4.00 |
| Feb-27-25 | Downgrade | B. Riley Securities | Buy → Neutral | |
| Feb-26-25 | Downgrade | HC Wainwright & Co. | Buy → Neutral | |
| Oct-22-24 | Reiterated | B.Riley Financial | Buy | |
| Sep-09-24 | Initiated | Leerink | Outperform | |
| Jun-10-24 | Reiterated | Goldman Sachs | Buy | $5.00 |
| Jun-10-24 | Reiterated | Stifel Nicolaus | Hold | |
| Apr-30-24 | Reiterated | Robert W. Baird | $4.50 | |
| Apr-30-24 | Downgrade | Baird | Outperform → Neutral |
Latest News· Times ET
Sep-18-26
Sep-18-2612:01PM
Sep-16-26
Sep-16-2605:03AM
Sep-14-26
Sep-14-2611:00AM
Sep-13-26
Sep-13-2606:02AM
Sep-02-26
Sep-02-2611:58AM
09:36AM
04:00AM
Geron to Present at Upcoming Investor Conferencesglobenewswire.com
Aug-26-26
Aug-26-2612:20AM
Aug-18-26
Aug-18-2612:01PM
05:58AM
Aug-13-26
Aug-13-2611:45PM
Aug-05-26
Aug-05-2608:53AM
07:00AM
Geron Corporation (GERN) Q2 2026 Earnings Call Transcriptseekingalpha.com
06:01AM
05:04AM
Geron Q2 Earnings Call Highlightsmarketbeat.com
Company
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 204 | 184 | 77 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 34 | 5 | 1 | — | — | — | — | — | — | |
| Gross Profit | 170 | 179 | 76 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 155 | 159 | 146 | — | — | — | — | — | — | |
| Research and Development | 74 | 74 | 104 | — | — | — | — | — | — | |
| Other Operating Expense | -22 | 0 | -1 | — | — | — | — | — | — | |
| Operating Income | -37 | -54 | -174 | — | — | — | — | — | — | |
| Interest Expense | 30 | 33 | 19 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -2 | 1 | 18 | — | — | — | — | — | — | |
| Net Income Before Taxes | -70 | -86 | -175 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -70 | -86 | -175 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -70 | -86 | -175 | — | — | — | — | — | — | |
| Net Income | -70 | -86 | -175 | — | — | — | — | — | — | |
| EPS (Recurring) | -0.10 | -0.13 | -0.27 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.10 | -0.13 | -0.27 | — | — | — | — | — | — | |
| EPS (Diluted) | -0.10 | -0.13 | -0.27 | — | — | — | — | — | — | |
| EBITDA | -42 | -52 | -155 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 4.28 | 4.79 | 29.70 | — | — | — | — | — | — | |
| Gross Margin | 83.33 | 97.28 | 98.70 | — | — | — | — | — | — | |
| Operating Margin | -18.14 | -29.35 | -225.97 | — | — | — | — | — | — | |
| Net Margin | -34.31 | -46.74 | -227.27 | — | — | — | — | — | — | |
| Shares Outstanding | 671 | 667 | 646 | — | — | — | — | — | — | |
| Market Capitalization | 872 | 880 | 2,287 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| ROBERTSON MICHELLE | EVP, CHIEF FINANCIAL OFFICER | Feb 18 '26 | Option Exercise | 0.00 | 27,500 | 0 | 27,500 | Feb 19 |
| ROBERTSON MICHELLE | EVP, CHIEF FINANCIAL OFFICER | Feb 18 '26 | Sale | 1.94 | 9,855 | 19,119 | 17,645 | Feb 19 |
| LAWLIS V BRYAN | Director | May 09 '25 | Buy | 1.18 | 13,300 | 15,667 | 13,300 | May 13 |
| Samuels Scott Alan | EVP, Chief Legal Officer | Feb 27 '25 | Buy | 1.61 | 15,000 | 24,150 | 26,682 | Mar 03 |
| SCARLETT JOHN A | Chairman, President and CEO | Feb 27 '25 | Buy | 1.76 | 12,500 | 22,063 | 12,500 | Mar 03 |
| Ziegler James | EVP, Chief Commercial Officer | Feb 27 '25 | Buy | 1.60 | 100,000 | 160,000 | 100,000 | Mar 03 |
| GRETHLEIN ANDREW J | EVP, Chief Operating Officer | Jul 08 '24 | Option Exercise | 1.72 | 1,127,152 | 1,938,702 | 674,348 | Jul 10 |
| GRETHLEIN ANDREW J | EVP, Chief Operating Officer | Jul 08 '24 | Sale | 4.56 | 674,348 | 3,073,004 | 0 | Jul 10 |
| Feller Faye | EVP, Chief Medical Officer | Jun 10 '24 | Option Exercise | 1.19 | 287,900 | 341,693 | 155,400 | Jun 12 |
| Feller Faye | EVP, Chief Medical Officer | Jun 10 '24 | Sale | 4.63 | 287,900 | 1,334,129 | 0 | Jun 12 |
| Kapur Anil | EVP, Corp Strategy & CCO | Jun 10 '24 | Option Exercise | 1.06 | 421,875 | 447,188 | 421,875 | Jun 12 |
| Kapur Anil | EVP, Corp Strategy & CCO | Jun 10 '24 | Sale | 4.64 | 421,875 | 1,959,609 | 0 | Jun 12 |
| SCARLETT JOHN A | Chairman, President and CEO | Jun 04 '24 | Sale | 4.00 | 600,000 | 2,400,000 | 600,000 | Jun 05 |
| SCARLETT JOHN A | Chairman, President and CEO | Jun 04 '24 | Option Exercise | 2.54 | 600,000 | 1,524,000 | 600,000 | Jun 05 |
| LAWLIS V BRYAN | Director | May 15 '24 | Option Exercise | 1.94 | 35,000 | 67,900 | 35,000 | May 17 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.